Sarepta Therapeutics Inc
(BSP:S1RP34)
R$
37.72
-0.52 (-1.36%)
Market Cap: 72.06 Bil
Enterprise Value: 73.29 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 79/100 Sarepta Therapeutics Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022 / 04:00PM GMT
Release Date Price:
R$18.82
(+1.13%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Good afternoon, and thank you for joining Guggenheim Genomic Medicines and Rare Disease Conference. I'm Debjit. I'm one of the analysts representing the Guggenheim Therapeutics team. My privilege to host Sarepta's President and CEO; Doug Ingram; and Executive Vice President and CFO, Ian Estepan. Thank you for your time today, gentlemen.
Questions & Answers
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
And with that, Doug, let me start with a broad question. 5 years since you started at Sarepta. How do you feel about the progress to date? And if there is anything you could have done differently, what's that?
Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director
I'm sure there's a lot of things I could have done differently. It's interesting, people who know me will say that I am perennially unsatisfied with everything. I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot